Low Dose Aprepitant for Patients Receiving Carboplatin
Status:
Recruiting
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
This study evaluates a simple one day prophylaxis of nausea and vomiting for patients who are
getting carboplatin based chemotherapy. In addition to standard oral dexmethasone and oral
ondansetrone, participants will be given a third neurokinin 1 (NK1) antagonist agent, either
Aprepitant or Fosaprepitant (they have been shown to be equally effective) to improve
prevention of nausea and vomiting. No medications need to be taken beyond day 1.
Phase:
Phase 2
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine, Inc.